Cash and Investments -- $301.8 million as of December 31, 2025, sufficient to fully fund current Phase III HCV and new HEV programs through 2027. Phase III HCV Trials -- C BEYOND enrollment completed ...
Good morning, and welcome to the CorMedix Fourth Quarter and Full Year 2025 Earnings and Corporate Update Conference Call. Leading the call tod ...
NEUTROGUARD study: Phase III clinical study of DEFENCATH for prevention of CLABSI in adults on TPN via central venous catheter.
Royce Premier Fund gained 5.6% in 2025, lagging its small-cap benchmark. Read the full analysis for more details.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results